Study offers new hope for the fight against genetically determined obesity

June 3, 2018, University of Copenhagen
Credit: CC0 Public Domain

Around 2 to 6 percent of all people with obesity develop the condition in early childhood. Obesity-causal mutations in one of the 'appetite genes' gives them a strong genetic predisposition for developing obesity, also called monogenic obesity. Their experience of hunger is overruling and their feeling of satiety limited.

In addition, this group of people with respond less well to existing treatments than others. Diets and surgery can help them lose weight, but the long-term effect is poor, as they are unable to maintain the weight loss.

Now, there is hope for this group of people. In a new study published in the scientific journal Cell Metabolism researchers at the University of Copenhagen have discovered that people with such a can lose weight with the help of liraglutide, a modified form of the appetite-inhibiting hormone GLP-1, naturally secreted from the intestines when eating.

"These people develop obesity because they are genetically programmed to do so. That is, they are struggling with what is probably the strongest human drive: the desire to eat and thus to survive. However, the appetite-inhibiting drug liraglutide has a positive effect on them. They feel less hungry and lose six percent of their body weight within four months," says the study leader, Associate Professor Signe Sørensen Torekov from the Department of Biomedical Sciences and the Novo Nordisk Foundation Center for Basic Metabolic Research.

Receptor Confusion

In this study the researchers have examined 14 persons with obesity caused by pathogenic mutations in the so-called MC4R gene and 28 persons with obesity without the mutations. Both groups were treated with the medicine for four months; no changes were made to their diet and level of exercise in this period.

The individuals with this most common form of monogenic obesity lost 7 kg of their body weight compared to 6 kg for the people with common obesity.

"We are positively surprised to see that the treatment has a good effect on this group of people. Many researchers have believed that the function of the medicine was mainly to inhibit the appetite by stimulating this specific appetite receptor in the brain which does not work in this particular group of people with obesity. However, our study shows that the medicine still has an appetite-inhibiting effect and thus must affect the appetite in a different way," says Signe Sørensen Torekov.

Medicine acting as an analogue to our natural GLP-1 hormone is already available, as it has been FDA and EMA licensed for the treatment of obesity and type 2 diabetes. The new study thus makes it possible to treat cases of the most common form of genetically caused obesity in which patients respond poorly to existing treatments.

"People who have suffered from obesity all their lives probably are not aware that it is caused by this mutation. It can therefore be a huge relief for many to learn why they have developed obesity and that there is actually a treatment that works," says first-author of the study, Ph.D. Student Eva Winning Iepsen at the Department of Biomedical Sciences and the Novo Nordisk Foundation Center for Basic Metabolic Research.

She also points out that the medicine makes it easier for people with this monogenic form of obesity to control their blood sugar. The can thus also have an effect on diabetes and pre-diabetes often seen in this particular group of individuals with genetically determined obesity.

As MC4R mutations cause obesity already in early childhood, the researchers hope the results can pave the way for new studies on young people in the future. If they are able to prevent this condition before the young people reach adulthood, it will have a great positive effect on their health and perhaps also social stigmatization, the researchers believe.

Explore further: New diabetes drug may help people with obesity lose weight

More information: Eva W. Iepsen et al, Patients with Obesity Caused by Melanocortin-4 Receptor Mutations Can Be Treated with a Glucagon-like Peptide-1 Receptor Agonist, Cell Metabolism (2018). DOI: 10.1016/j.cmet.2018.05.008

Related Stories

New diabetes drug may help people with obesity lose weight

March 18, 2018
A compound that mimics a naturally occurring hormone that regulates appetite may help people who have obesity but not diabetes to lose weight, a new study suggests. The research will be presented Sunday, March 18, at ENDO ...

New obesity treatment prevents bone loss during weight loss

June 10, 2015
Using the intestinal hormone GLP-1 in obesity treatment prevents the loss of bone mass otherwise frequently associated with major weight loss. This is the finding of a new study from the University of Copenhagen, Hvidovre ...

Obese people can maintain stable weight loss

April 14, 2016
Maintaining a stable weight loss is the biggest struggle for obese individuals, yet new research from University of Copenhagen have allowed researchers new insights into the complex processes involved in obesity and especially ...

A new drug to help young patients with genetic obesity

May 9, 2018
In a new study, researchers from the Institute for Experimental Pediatric Endocrinology of the Charité - Universitätsmedizin Berlin have successfully treated patients whose obesity is caused by a genetic defect. Aside from ...

Obesity linked with higher chance of developing rapid, irregular heart rate

April 18, 2018
People with obesity are more likely to develop a rapid and irregular heart rate, called atrial fibrillation, which can lead to stroke, heart failure and other complications, according to Penn State researchers.

Trial shows drug can dramatically reduce weight of people with obesity

October 23, 2017
A drug that targets the appetite control system in the brain could bring about significant weight loss in people with clinical obesity, according to new research.

Recommended for you

Obesity plagues rural America

June 19, 2018
(HealthDay)—Country folk are being hit harder by the U.S. obesity epidemic than city dwellers, two new government studies show.

Binging, purging and fasting more common in overweight, obese young adults

June 12, 2018
Young adults who are overweight or obese are twice as likely as their leaner peers to binge and purge, use laxatives or diuretics, or force themselves to vomit as a means of controlling their weight, according to a new study ...

Study offers new hope for the fight against genetically determined obesity

June 3, 2018
Around 2 to 6 percent of all people with obesity develop the condition in early childhood. Obesity-causal mutations in one of the 'appetite genes' gives them a strong genetic predisposition for developing obesity, also called ...

Abnormal lipid metabolism in fat cells predicts future weight gain and diabetes in women

May 31, 2018
The inefficient breakdown of fats predicts later weight gain and metabolic complications such as type 2 diabetes in women, researchers report May 31 in the journal Cell Metabolism. Low levels of hormone-stimulated lipolysis—a ...

Antidepressant use may contribute to long-term population weight gain

May 24, 2018
Researchers at King's College London have found that patients prescribed any of the 12 most commonly used antidepressants were 21% more likely to experience an episode of gain weight than those not taking the drugs, (after ...

Bid to beat obesity focuses on fat that keeps us warm

May 24, 2018
A new technique to study fat stores in the body could aid efforts to find treatments to tackle obesity.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.